This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
Roving Reporter Asks: How Should We Redefine Value, Access, and Affordability in Cell and Gene Therapy?
IBTV speaks with industry leaders at ASGCT 2026 about new approaches to manufacturing, reimbursement, treatment delivery, and long-term value that could bring cell and gene therapies to more patients
09/11/2026
1 min read
Video
